In addition to our current blogs (www.ptjourneys.com and www.biosiosimilarsrr.com), here is a sampling of recent publications and articles developed by SM Health Communications LLC:

  • Mehr SR: Where the US Biosimilars Market Is Heading and When It Might Get There. SM Health Communications February 2020. https://biosimilarsrr.com/our-biosimilars-market-report/.
  • Mehr SR, Brook RA:  Biosimilars in the USA: Will new efforts to spur approvals and access spur uptake and cost savings? Pharmaceutical Medicine 2019; https://doi.org/10.1007/s40290-018-00262-z.
  • Mehr SR: If four-letter suffixes aren’t used in biosimilar tracking, what use are they? Biosimilar Development. November 6, 2018. https://www.biosimilardevelopment.com/doc/if-four-letter-suffixes-aren-t-used-in-biosimilar-tracking-what-use-are-they-0001.
  • Mehr SR, Renfro M: The Patient’s Paramount Place: Emphasis on Empowerment, Engagement, Experience. Academy of Managed Care Pharmacy Foundation. August 2018. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=23845.
  • Mehr SR, Reinert A: The Rx affordability crisis. Academy of Managed Care Pharmacy Foundation. September 2017. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=22747
  • Mehr SR, Brook RA: Factors influencing the economics of biosimilars in the US. J Med Econ 2017;20(12):1268-1271. doi:10.1080/13696998.2017.1366325.
  • Mehr SR: Pharmaceutical patent litigation and the emerging biosimilars: A conversation with Kevin M. Nelson, JD. Am Health Drug Benefits. 2017;10(1):23-26.
  • Mehr SR: Maximizing Value in Health Care. Academy of Managed Care Pharmacy Foundation. June 2017 http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=22527.
  • Mehr SR, Zimmerman MP: Is a biologic produced 15 years ago a biosimilar of itself today? Am Health Drug Benefits. 2016;9(9):515-518.
  • Mehr SR: Will the PCSK9 inhibitors be employers’ “line in the sand”? Am Health Drug Benefits 2016;9(3):171-174.
  • Mehr SR: Payer perspectives on PCSK9 inhibitors: A conversation with Stephen Gorshow, MD, and James T. Kenney, RPh, MBA. Am Health Drug Benefits. 2016;9(1):38-41.
  • Mehr SR: AMCP Market Insights: Focus on Psoriasis. American Medical Communications, Manalpan, NJ, June 2016.
  • Mehr SR: Ahead of the curve: Emerging trends implications for policy-makers and patients. Academy of Managed Care Pharmacy Foundation. September 2016. http://www.amcp.org/ET_Whitepaper/.
  • Mehr SR: The Top 5 Health Benefits/Delivery Trends Affecting Oncology Business Practices. Oncology Practice Management 2016;2(6). (http://oncpracticemanagement.com/issue-archive/special-issues/innovations-oncology-management-vol-2-no-6/top-5-health-benefits-delivery-trends-affecting-oncology-business-practices/)
  • Opportunities and Challenges in Patient Care, Prevention, and Adherence. AMCP Foundation, http://www.amcp.org/2015_SymposiumSummary/. October 26, 2015.
  • Mehr SR, Zimmerman MP: Reviewing the Unmet Needs in Multiple Sclerosis. Am Health Drug Benefits. 2015;8(8):426-431.